Applications are welcome from individuals with an MD, PhD, DO or PharmD who are affiliated with a facility that utilizes IGIV in a basic or clinical science research setting or to treat patients. Such facilities may include, but are not limited to, universities, hospitals, clinics, blood centers, and laboratories.
The Talents Program has three key aims:
* Further the understanding of the efficacy and mechanisms of action of IGIV in current clinical indications
* Explore new clinical uses of IGIV
* Support the intellectual endeavors of the IGIV research community.
Grants are usually made for either a one- or two-year period and include support for salary, overheads, and direct costs. Product may also be provided. The program seeks to disburse individual grants of up to $150,000 per research project, excluding product costs.
***The funding cycle takes place on an annual basis. Letters of Intent are due August 15, selected full proposals are due October 15, and funding begins in January of the following year.***
Deadline: Check deadline
Funder: Talecris Biotherapeutics, Inc
Stage of Study: